Who
Kelly Schick
Chief People Officer
Company insider
Files Form 4 as: Chief People Officer, C4 Therapeutics; Chief Human Resources Officer, Amag Pharmaceuticals.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 23 Feb 2020
- Last trade
- 14 Feb 2026
- Last filed
- 18 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,950 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K7,269 at $1.89 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,950 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K7,269 at $1.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,2791,735 at $1.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,2791,735 at $1.89 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,700 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —56,500 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,5302,368 at $3.18 | filing |
| 13 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,5521,735 at $3.20 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $6,6561,102 at $6.04 | filing |
| 16 Sep 2024filed 17 Sep 2024 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,250 at $0.00 | filing |
| 16 Sep 2024filed 17 Sep 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,250 | filing |
| 16 Sep 2024filed 17 Sep 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,204661 at $6.36 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.